TORONTO, May 18 /CNW/ - The common shares of Pivotal Therapeutics Inc.
have been approved for listing on CNSX. The Company has 68,986,117
common shares outstanding with a public float of approximately 49.6
Pivotal is a re-profiling specialty pharmaceutical company that creates
novel uses for currently marketed or near market drugs or therapeutics.
Pivotal's first product, VASCAZENTM, is a prescription-only medical
food to be used for the clinical dietary management of cardiovascular
disease in patients with documented coronary heart disease (CHD),
deficient in blood omega-3 fatty acid, Eicosapentaenoic Acid (EPA) and
Docosahexaenoic Acid (DHA) levels.
Listing and disclosure documents for Pivotal Therapeutics Inc. will be
available in the CNSX Listings Disclosure Hall.
Trading Date: Thursday, May 19, 2011
CUSIP: 72582E 10 4
ISIN: CA 72582E 10 4 3
Applications are being accepted for Market Makers for "PVO ".
SOURCE Canadian National Stock Exchange (CNSX)
For further information:
If you have any questions or require further information please contact Radhika at (416) 572-2000 X 2435 or E-mail: firstname.lastname@example.org